APOL6 predicts immunotherapy efficacy of bladder cancer by ferroptosis

Abstract Background Immune checkpoint inhibitors (ICIs) are rapidly evolving in the management of bladder cancer (BLCA). Nevertheless, effective biomarkers for predicting immunotherapeutic outcomes in BLCA are still insufficient. Ferroptosis, a form of immunogenic cell death, has been found to enhan...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:BMC Cancer
المؤلفون الرئيسيون: Zhiwei Fan, Yiting Liu, Xuehai Wang, Yuting Xu, Ruiyao Huang, Weijian Shi, Yi Qu, Jialing Ruan, Chu Zhou, Xinyuan Zhao, Lei Liu
التنسيق: مقال
اللغة:الإنجليزية
منشور في: BMC 2024-08-01
الموضوعات:
APOL6
Bladder cancer (BLCA)
Immunotherapy
Ferroptosis
الوصول للمادة أونلاين:https://doi.org/10.1186/s12885-024-12820-7

الانترنت

https://doi.org/10.1186/s12885-024-12820-7

مواد مشابهة